Consensus PHAXIAM Therapeutics S.A.

Equities

PHXM

FR001400K4B1

End-of-day quote Euronext Paris Other stock markets 23:00:00 05/05/2024 BST			5-day change	1st Jan Change
2.925 ^EUR	+1.74%		-1.18%	-36.41%

04-15	Phaxiam initiates trial in infective endocarditis	CF
04-15	PHAXIAM Therapeutics Announces Enrolment of First Patient in the Phase 1 Study for the Treatment of Endocarditis Infections Caused by Staphylococcus Aureus	CI

Evolution of the average Target Price on PHAXIAM Therapeutics S.A.

Price target over the last 5 years

History of analyst recommendation changes

b40aebcde08f1de593fc09da.908XessbgT-GOTs6r_Ao9qDXLratC4K4-hQGiKf0BW0.hQJICr507m3eQGEKzaFOtcq_d8DFP7DiuCZS6uDCXx2OJVQdhEzmZuhXag~0b1f096cf328144b2b2348ac7fe4143b